Cardiovascular Disease Clinical Trial
Official title:
The Orange Juice and Cardiovascular Disease Study
This study aims to compare the effect of an anthocyanin-rich blood orange juice with a
standard (no anthocyanin) blonde orange juice on markers of cardiovascular disease (CVD).
Participants aged between 25 and 84 years of age will be recruited into a single arm, two
way cross-over study based on their waist measurement, with 42 individuals required to
complete the study. Participants will each receive two interventions in a randomised order:
500mL blood orange juice daily for 28 days, and 500ml standard (blonde) orange juice daily
for 28 days.
Prior to each intervention there will be a 2 week "run in period" where participants will be
asked to avoid consuming foods rich in anthocyanins. After the first 28 day intervention
period, there will be a 3 week wash out period after which the participants will be asked to
then drink the other juice for 28 days. The 500 mL of blood orange juice contains
approximately 50mg of anthocyanins, whereas the standard juice contains none.
Blood samples will be collected for the preparation of plasma and peripheral blood
mononuclear cells (PBMCs) for the analysis of anthocyanin metabolite concentrations,
transcriptomics and CVD risk markers. Urine samples will be collected and urinary excretion
of anthocyanin metabolites will be quantified. Other measurements will include pulse wave
analysis, pulse wave velocity, central blood pressure, waist and hip circumference, blood
glucose, glycated haemoglobin (HbA1C) and insulin concentrations, and various measurements
using the TANITA machine which include weight, fat mass, muscle mass, fat percentage,
fat-free mass, total body water, bone mass, metabolic age, basal metabolic rate, visceral
fat rating, and degree of obesity. All measurements and samples will be taken at baseline
and post intervention for each phase of the study.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02122198 -
Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
|
N/A | |
Completed |
NCT02502812 -
Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04216342 -
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03654313 -
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
|
Phase 1 | |
Completed |
NCT03646656 -
Heart Health Buddies: Peer Support to Decrease CVD Risk
|
N/A | |
Completed |
NCT02081066 -
Identification of CETP as a Marker of Atherosclerosis
|
N/A | |
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT06405880 -
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
|
N/A | |
Recruiting |
NCT03095261 -
Incentives in Cardiac Rehabilitation
|
N/A | |
Completed |
NCT02868710 -
Individual Variability to Aerobic Exercise Training
|
N/A | |
Completed |
NCT02711878 -
Healing Hearts and Mending Minds in Older Adults Living With HIV
|
N/A | |
Completed |
NCT02589769 -
Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons
|
N/A | |
Completed |
NCT02998918 -
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL
|
N/A | |
Not yet recruiting |
NCT02578355 -
National Plaque Registry and Database
|
N/A | |
Recruiting |
NCT02885792 -
Coronary Artery Disease in Patients Suffering From Schizophrenia
|
N/A | |
Completed |
NCT02657382 -
Mental Stress Ischemia: Biofeedback Study
|
N/A | |
Completed |
NCT02640859 -
Investigation of Metabolic Risk in Korean Adults
|
||
Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A | |
Completed |
NCT02272946 -
Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk
|
Phase 2 | |
Recruiting |
NCT02265250 -
Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
|